It looks like you're new here. If you want to get involved, click one of these buttons!
div>Participants were 30�C60?years old with a mean age of 46.9?years. Nearly all participants (97%) were of Danish nationality. Ethnicity was not recorded. The Inter99 Eye Study was designed to include a predefined overrepresentation of subjects with cardiovascular disease high-risk characteristics. Consequently, the subgroup of participants in the Inter99 study that participated in the Inter99 Eye Study had higher blood pressure, less favourable lipid profiles, and a higher prevalence of impaired glucose tolerance than the overall Inter99 study population (Table?1). Any retinopathy (ETDRS level ��15) was found in 8.3% (CI95 6.3�C10.3%) of all subjects in the eye study and mild retinopathy or worse (ETDRS level ��35) was found in 1.1% of subjects (Table?1). In the age-stratified sample of subjects from the Inter99 study population, the prevalence of any retinopathy was 7.3% (CI95 4.9�C9.6%) Cisplatin whereas it was 10.4% (CI95 6.5�C14.4%) in the subjects selected from the cardiovascular disease high-risk group in 3-Methyladenine mouse the Inter99 study (Table?2). This difference in prevalence of retinopathy between ascertainment groups did not reach statistical significance (Table?2). There were no significant interactions between the ascertainment groups and the tested variables, meaning that the associations between retinopathy and risk factors were similar in the two ascertainment groups. Therefore, we present only the results of the combined analysis. The prevalence of retinopathy was higher in the oldest decade (9.3%) than in the youngest decade (6.6%) but the difference did not reach statistical significance (Table?2). No association MEK inhibitor with sex, daily smoking or levels of serum lipids was observed (Table?2). Systolic blood pressure was significantly associated with the presence of retinopathy with an odds ratio (OR) of 3.37 (CI95 1.40�C8.10, p?=?0.0068, adjusted for age and sex) in subjects with SBP ��160?mmHg compared to subjects with SBP <130?mmHg and with a significant increase in the prevalence of retinopathy with increasing SBP (p?=?0.032; Table?2). No significant association was observed between retinopathy and increasing diastolic blood pressure or with arterial hypertension as defined by the JNC7-classification (Chobanian et?al. 2003) (Table?2). Markers of long-term glycaemia such as HbA1c and lens fluorescence were not associated with retinopathy (Table?3). There was no significant association between retinopathy and FPG or 2-hr plasma glucose values from the oral glucose tolerance test (Table?3). The prevalence of retinopathy was 11.7% in subjects with FPG 6.1�C6.9?mm (impaired fasting glucose) compared with 5.9% in subjects with FPG <5.0?mm, a difference that did not reach statistical significance in the age- and sex-adjusted analysis [OR 2.05 (CI95 0.70�C5.97, p?=?0.19)].